These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 36348252)

  • 1. FUT8 is regulated by miR-122-5p and promotes malignancies in intrahepatic cholangiocarcinoma via PI3K/AKT signaling.
    Chen F; Li Y; Aye L; Wu Y; Dong L; Yang Z; Gao Q; Zhang S
    Cell Oncol (Dordr); 2023 Feb; 46(1):79-91. PubMed ID: 36348252
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MUC13 promotes intrahepatic cholangiocarcinoma progression via EGFR/PI3K/AKT pathways.
    Tiemin P; Fanzheng M; Peng X; Jihua H; Ruipeng S; Yaliang L; Yan W; Junlin X; Qingfu L; Zhefeng H; Jian L; Zihao G; Guoxing L; Boshi S; Ming Z; Qinghui M; Desen L; Lianxin L
    J Hepatol; 2020 Apr; 72(4):761-773. PubMed ID: 31837357
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CircZNF215 promotes tumor growth and metastasis through inactivation of the PTEN/AKT pathway in intrahepatic cholangiocarcinoma.
    Liao W; Du J; Li L; Wu X; Chen X; Feng Q; Xu L; Chen X; Liao M; Huang J; Yuan K; Zeng Y
    J Exp Clin Cancer Res; 2023 May; 42(1):125. PubMed ID: 37198696
    [TBL] [Abstract][Full Text] [Related]  

  • 4. miR-885-5p inhibits proliferation and metastasis by targeting IGF2BP1 and GALNT3 in human intrahepatic cholangiocarcinoma.
    Lixin S; Wei S; Haibin S; Qingfu L; Tiemin P
    Mol Carcinog; 2020 Dec; 59(12):1371-1381. PubMed ID: 33052627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ST3GAL1 Promotes Malignant Phenotypes in Intrahepatic Cholangiocarcinoma.
    Chen F; Gao K; Li Y; Li Y; Wu Y; Dong L; Yang Z; Shi J; Guo K; Gao Q; Lu H; Zhang S
    Mol Cell Proteomics; 2024 Sep; 23(9):100821. PubMed ID: 39069074
    [TBL] [Abstract][Full Text] [Related]  

  • 6. miR-181b-5p Promotes the Progression of Cholangiocarcinoma by Targeting PARK2 via PTEN/PI3K/AKT Signaling Pathway.
    Jiang ZL; Zhang FX; Zhan HL; Yang HJ; Zhang SY; Liu ZH; Jiang Y; Lv LZ; Ke RS
    Biochem Genet; 2022 Feb; 60(1):223-240. PubMed ID: 34169384
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Hippo pathway effector TAZ induces intrahepatic cholangiocarcinoma in mice and is ubiquitously activated in the human disease.
    Cigliano A; Zhang S; Ribback S; Steinmann S; Sini M; Ament CE; Utpatel K; Song X; Wang J; Pilo MG; Berger F; Wang H; Tao J; Li X; Pes GM; Mancarella S; Giannelli G; Dombrowski F; Evert M; Calvisi DF; Chen X; Evert K
    J Exp Clin Cancer Res; 2022 Jun; 41(1):192. PubMed ID: 35655220
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epigenetic dysregulation-mediated COL12A1 upregulation predicts worse outcome in intrahepatic cholangiocarcinoma patients.
    Tang Z; Yang Y; Zhang Q; Liang T
    Clin Epigenetics; 2023 Jan; 15(1):13. PubMed ID: 36694230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protein tyrosine phosphatase PTP4A1 promotes proliferation and epithelial-mesenchymal transition in intrahepatic cholangiocarcinoma via the PI3K/AKT pathway.
    Liu LZ; He YZ; Dong PP; Ma LJ; Wang ZC; Liu XY; Duan M; Yang LX; Shi JY; Zhou J; Fan J; Gao Q; Wang XY
    Oncotarget; 2016 Nov; 7(46):75210-75220. PubMed ID: 27655691
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Knockdown of tripartite motif 59 (TRIM59) inhibits proliferation in cholangiocarcinoma via the PI3K/AKT/mTOR signalling pathway.
    Shen H; Zhang J; Zhang Y; Feng Q; Wang H; Li G; Jiang W; Li X
    Gene; 2019 May; 698():50-60. PubMed ID: 30822475
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MiR-206 suppresses the deterioration of intrahepatic cholangiocarcinoma and promotes sensitivity to chemotherapy by inhibiting interactions with stromal CAFs.
    Yang R; Wang D; Han S; Gu Y; Li Z; Deng L; Yin A; Gao Y; Li X; Yu Y; Wang X
    Int J Biol Sci; 2022; 18(1):43-64. PubMed ID: 34975317
    [No Abstract]   [Full Text] [Related]  

  • 12. Exosomal miR-30a-5p promoted intrahepatic cholangiocarcinoma progression by increasing angiogenesis and vascular permeability in PDCD10 dependent manner.
    Jiang W; Shi X; Sun L; Zhang Y; Kong X; Yang X; Yin Y; Li C; Li X
    Int J Biol Sci; 2023; 19(14):4571-4587. PubMed ID: 37781039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exosome-derived miR-182-5p promoted cholangiocarcinoma progression and vasculogenesis by regulating ADK/SEMA5a/PI3K pathway.
    Wang J; Jiang W; Liu S; Shi K; Zhang Y; Chen Y; Shan J; Wang Y; Xu X; Li C; Li X
    Liver Int; 2024 Feb; 44(2):370-388. PubMed ID: 37950359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tetraspanin 1 promotes epithelial-to-mesenchymal transition and metastasis of cholangiocarcinoma via PI3K/AKT signaling.
    Wang Y; Liang Y; Yang G; Lan Y; Han J; Wang J; Yin D; Song R; Zheng T; Zhang S; Pan S; Liu X; Zhu M; Liu Y; Cui Y; Meng F; Zhang B; Liang S; Guo H; Liu Y; Hassan MK; Liu L
    J Exp Clin Cancer Res; 2018 Dec; 37(1):300. PubMed ID: 30514341
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epigenetic deregulation of MLF1 drives intrahepatic cholangiocarcinoma progression through EGFR/AKT and Wnt/β-catenin signaling.
    Tang Z; Yang Y; Chen W; Liang T
    Hepatol Commun; 2023 Aug; 7(8):. PubMed ID: 37486965
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long non-coding RNA MALAT1 promotes cholangiocarcinoma cell proliferation and invasion by activating PI3K/Akt pathway.
    Wang C; Mao ZP; Wang L; Wu GH; Zhang FH; Wang DY; Shi JL
    Neoplasma; 2017; 64(5):725-731. PubMed ID: 28592124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SSH1 promotes progression of intrahepatic cholangiocarcinoma via p38 MAPK-CXCL8 axis.
    Chen F; Aye L; Yu L; Liu L; Liu Y; Lin Y; Gao D; Gao Q; Zhang S
    Carcinogenesis; 2023 May; 44(3):232-241. PubMed ID: 36857607
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MicroRNA-155-5p promotes hepatocellular carcinoma progression by suppressing PTEN through the PI3K/Akt pathway.
    Fu X; Wen H; Jing L; Yang Y; Wang W; Liang X; Nan K; Yao Y; Tian T
    Cancer Sci; 2017 Apr; 108(4):620-631. PubMed ID: 28132399
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrative analysis reveals different feature of intrahepatic cholangiocarcinoma subtypes.
    Chen Z; Gao J; Li Z; Ma D; Wang Y; Cheng Q; Zhu J; Li Z
    Liver Int; 2024 Sep; 44(9):2477-2493. PubMed ID: 38924592
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cancer-associated fibroblasts promote tumor cell growth via miR-493-5p in intrahepatic cholangiocarcinoma.
    Toshida K; Itoh S; Harada N; Morinaga A; Yugawa K; Tomiyama T; Kosai-Fujimoto Y; Tomino T; Kurihara T; Nagao Y; Morita K; Oda Y; Yoshizumi T
    Cancer Sci; 2023 Mar; 114(3):937-947. PubMed ID: 36369960
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.